The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a low 5-year survival rate, yet new immunotherapeutic modalities may offer hope for this and other intractable cancers. Here, we report that inhibitory targeting of PI3Kγ, a key macrophage lipid kinase, stimulates antitumor immune responses, leading to improved survival and responsiveness to standard-of-care chemotherapy in animal models of PDAC. PI3Kγ selectively drives immunosuppressive transcriptional programming in macrophages that inhibits adaptive immune responses and promotes tumor cell invasion and desmoplasia in PDAC. Blockade of PI3Kγ in PDAC-bearing mice reprograms tumor-associated macrophages to stimulate CD8+ T-cell–mediated tumor suppression and to inhibit tumor cell invasion, metastasis, and desmoplasia. These data indicate the central role that macrophage PI3Kγ plays in PDAC progression and demonstrate that pharmacologic inhibition of PI3Kγ represents a new therapeutic modality for this devastating tumor type. Significance: We report here that PI3Kγ regulates macrophage transcriptional programming, leading to T-cell suppression, desmoplasia, and metastasis in pancreas adenocarcinoma. Genetic or pharmacologic inhibition of PI3Kγ restores antitumor immune responses and improves responsiveness to standard-of-care chemotherapy. PI3Kγ represents a new therapeutic immune target for pancreas cancer. Cancer Discov; 6(8); 870–85. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 803
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Self-citationDynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
PI3K signalling: the path to discovery and understanding
Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3290 · Cited by 987
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770
Biswas, S. K. (2006) · Blood · doi:10.1182/blood-2005-01-0428 · Cited by 696
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
El Kasmi, K. C., Qualls, J. E., Pesce, J. T., Smith, A. M., Thompson, R. W., Henao-Tamayo, M., Basaraba, R. J., König, T., Schleicher, U., Koo, M.-S., et al. (2008) · Nature Immunology · doi:10.1038/ni.1671 · Cited by 646
Bardeesy, N., Aguirre, A. J., Chu, G. C., Cheng, K.-H., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 581
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Self-citationMutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466
Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
Self-citationTargeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
Stromnes, I. M., Brockenbrough, J. S., Izeradjene, K., Carlson, M. A., Cuevas, C., Simmons, R. M., Greenberg, P. D., & Hingorani, S. R. (2014) · Gut · doi:10.1136/gutjnl-2013-306271 · Cited by 331
Beatty, G. L., Winograd, R., Evans, R. A., Long, K. B., Luque, S. L., Lee, J. W., Clendenin, C., Gladney, W. L., Knoblock, D. M., Guirnalda, P. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.010 · Cited by 293
Soond, D. R., Bjørgo, E., Moltu, K., Dale, V. Q., Patton, D. T., Torgersen, K. M., Galleway, F., Twomey, B., Clark, J., Gaston, J. S. H., et al. (2010) · Blood · doi:10.1182/blood-2009-07-232330 · Cited by 195
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice
Collins, M. A., Brisset, J.-C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., Galbán, C. J., Galbán, S., & di Magliano, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049707 · Cited by 178
Platelet-derived growth factor receptors: A therapeutic target in solid tumors
George, D. W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90100-9 · Cited by 159
Keenan, B. P., Saenger, Y. M., Kafrouni, M. I., Leubner, A., Lauer, P., Maitra, A., Rucki, A. A., Gunderson, A. J., Coussens, L. M., Brockstedt, D. G., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.055 · Cited by 150
Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours
Joensuu, H., & Dimitrijević, S. (2001) · Annals of Medicine · doi:10.3109/07853890109002093 · Cited by 120
Karakhanova, S., Link, J., Heinrich, M., Shevchenko, I., Yang, Y., Hassenpflug, M., Bunge, H., von Ahn, K., Brecht, R., Mathes, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.998519 · Cited by 118
Schmid, M. C., Avraamides, C. J., Foubert, P., Shaked, Y., Kang, S. W., Kerbel, R. S., & Varner, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0588 · Cited by 115
Self-citationVaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer
Cappello, P., Rolla, S., Chiarle, R., Principe, M., Cavallo, F., Perconti, G., Feo, S., Giovarelli, M., & Novelli, F. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.020 · Cited by 110
Self-citationDevelopment of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host
Tseng, W. W., Winer, D. A., Kenkel, J. A., Choi, O., Shain, A. H., Pollack, J. R., French, R., Lowy, A. M., & Engleman, E. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2384 · Cited by 90
Self-citationRole of Arginase 1 from Myeloid Cells in Th2-Dominated Lung Inflammation
Barron, L., Smith, A. M., Kasmi, K. C. E., Qualls, J. E., Huang, X., Cheever, A. W., Borthwick, L. A., Wilson, M. S., Murray, P. J., & Wynn, T. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061961 · Cited by 89
Shi, C., Washington, M. K., Chaturvedi, R., Drosos, Y., Revetta, F. L., Weaver, C., Buzhardt, E., Yull, F. E., Blackwell, T. S., Sosa‐Pineda, B., et al. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.10 · Cited by 88
Phosphoinositide 3–kinase γ participates in T cell receptor–induced T cell activation
Alcázar, I., Marqués, M., Kumar, A., Hirsch, E., Wymann, M. P., Carrera, A. C., & Barber, D. F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070366 · Cited by 88
Self-citationMartin, A. L., Schwartz, M. D., Jameson, S. C., & Shimizu, Y. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2081 · Cited by 82
Myeloid cells in tumor inflammation
Schmid, M. C., & Varner, J. A. (2012) · Vascular Cell · doi:10.1186/2045-824x-4-14 · Cited by 71
Self-citationSchmid, M. C., Franco, I., Kang, S. W., Hirsch, E., Quilliam, L. A., & Varner, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060226 · Cited by 69
Self-citationPalanki, M. S. S., Dneprovskaia, E., Doukas, J., Fine, R., Hood, J. D., Kang, X., Lohse, D., Martin, M., Noronha, G., Söll, R., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm051056c · Cited by 61
Drugs in Phase II clinical trials for the treatment of age-related macular degeneration
Tolentino, M. J., Dennrick, A., John, E. S., & Tolentino, M. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.961601 · Cited by 60
Zeng, L., Guo, Y., Liang, J., Chen, S., Peng, P., Zhang, Q., Su, H., Chen, Y., & Huang, K. (2014) · Journal of Cancer · doi:10.7150/jca.10238 · Cited by 54
Chu, N. J., Armstrong, T. D., & Jaffee, E. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1186 · Cited by 43
Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer
Liou, G., & Störz, P. (2015) · Oncoscience · doi:10.18632/oncoscience.151 · Cited by 32
Phosphoinositide 3‐kinase gamma; participates in T cell receptor‐induced T cell activation.
Alcázar, I., Marqués, M., Kumar, A., Hirsch, E., Wymann, M. P., Carrera, A. C., & Barber, D. F. (2008) · The FASEB Journal · doi:10.1096/fasebj.22.1_supplement.1064.12 · Cited by 29
Self-citationStörz, P. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008794 · Cited by 21
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Metadata
- Authors
- Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., Lowy, A. M., Valasek, M. A., Sasik, R., Novelli, F., Hirsch, E., & Varner, J. A.
- Venue
- Cancer Discovery
- Published
- 2016-08-01
- Volume
- 6
- Issue
- 8
- Pages
- 870-885
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2359522094
- Cited by
- 326
- References
- 50
- FWCI
- 14.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.